Spero's Scientific Exchange

Posters and Publications

Filter all Posters & Publications

Download a complete bibliography from each of our ongoing investigational programs below.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Resource Type
Year
Congress
Study Type
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
SPR720
Tebipenem HBr
SPR206

Tebipenem HBR

No items found.

In vitro activity of tebipenem against relevant clinical isolates in the presence of pulmonary surfactant

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

In vitro activity of tebipenem and comparators against Enterobacterales collected from patients with bloodstream infections as part of the 2019 global STEWARD surveillance program 

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology
Clinical
HEOR

High prevalence of fluoroquinolone-resistant urinary tract infection among US emergency department patients diagnosed with UTI, 2018-2020

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Molecular epidemiology of Escherichia coli causing urinary tract infections in United States and in vitro activity of tebipenem, including against strain lineage and resistant subsets (2018–2020)

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Epidemiology and 12-month antibiotic use in the outpatient setting among adult patients with complicated urinary tract infections: a retrospective database analysis

2021
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Non-Clinical
PK/PD

A validated sensitive and selective ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method for quantitative analysis of tebipenem pivoxil and tebipenem, in human whole blood and its application in a pharmacokinetic study in healthy human volunteers

2021
WRIB
ARCHIVE
View Full Text Link
Open Resource

SPR206

PK/PD

Bruss J, Lister T, Gupta VK, et al. Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Polymyxin Derivative SPR206. Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0073921.

2021
Clinical
ARCHIVE
View Full Text Link
Open Resource

SPR720

PK/PD

Talley AK, Thurston A, Moore G, et al. First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections. Antimicrob Agents Chemother. 2021 Sep 7:AAC0120821.

2021
Clinical
ARCHIVE
View Full Text Link
Open Resource

SPR720

No items found.

Pidot SJ, Porter JL, Lister T, Stinear TP. In vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera. PLoS Negl Trop Dis. 2021 Jul 26;15(7):e0009636. 

2021
Microbiology
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

PK/PD

Pharmacokinetics of oral tebipenem pivoxil hydrobromide in subjects with varying degrees of renal impairment

2021
ECCMID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Agar dilution versus broth microdilution of tebipenem against ESBL-producing Enterobacterales 

2021
World Microbe Forum
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

In vitro minimum inhibitory and minimum bactericidal concentrations of tebipenem and comparators against contemporary Enterobacterales tested in pooled human urine at varied pH

2021
World Microbe Forum
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Activity of tebipenem against a set of recent clinical isolates from urinary tract and upper respiratory tract infections

2021
World Microbe Forum
ARCHIVE
View Full Text Link
Open Resource

SPR720

Microbiology

Characterization of resistance to DNA gyrase inhibitor SPR719 in Mycobacterium avium

2021
World Microbe Forum
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

No items found.

Gupta VK, Maier G, Eckburg P, et al. A randomized, double-blind, placebo- and positive-controlled crossover study of the effects of tebipenem pivoxil hydrobromide on QT/QTc intervals in healthy subjects. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0014521.

2021
Clinical
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

No items found.

Lodise TP, Chopra T, Nathanson BH, Sulham K. Hospital admission patterns of adult patients with complicated urinary tract infections who present to the hospital by disease acuity and comorbid conditions: How many admissions are potentially avoidable? Am J Infect Control. 2021 May 30:S0196-6553(21)00382-5.

2021
HEOR
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical

Oral tebipenem pivoxil hydrobromide is non-inferior to IV ertapenem in complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) – Results from the pivotal ADAPT-PO study.

2021
MAD-ID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Health resource utilization in patients with complicated urinary tract infections (cUTI) and antibiotic resistance or treatment failure: a retrospective database analysis

2021
MAD-ID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Tebipenem: An oral carbapenem with activity against multi-drug resistant urinary tract infection isolates of Escherichia coli collected from US medical centers during 2019

2021
MAD-ID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Epidemiology of complicated urinary tract infections (cUTIs) presenting in emergency departments across the United States (US)

2021
MAD-ID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Clinical characteristics and demographics of patients with complicated urinary tract infections (cUTI) and antibiotic resistance or treatment failure: a retrospective database analysis

2021
MAD-ID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Eligibility and outcomes of conversion to oral (PO) therapy in patients hospitalized with Enterobacteriaceae (ENT) urinary tract infection (UTI) in the United States (US): a multicenter analysis

2021
MAD-ID
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Hospital admission patterns in adult patients with complicated urinary tract infections: identification of potentially avoidable hospital admissions across US hospitals

2021
MAD-ID
ARCHIVE
View Full Text Link
Open Resource

SPR206

Microbiology

Brown P, Abdulle O, Boakes S, et al. Influence of  Lipophilicity on the Antibacterial Activity of Polymyxin Derivatives and on Their Ability to Act as Potentiators of Rifampicin. ACS Infect Dis. 2021 Apr 9;7(4):894-905.

2021
Non-Clinical
ARCHIVE
View Full Text Link
Open Resource

SPR720

No items found.

Pennings LJ, Ruth MM, Wertheim HFL, van Ingen J. The Benzimidazole SPR719 Shows Promising Concentration-Dependent Activity and Synergy against Nontuberculous Mycobacteria. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02469-20.

2021
Microbiology
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Non-Clinical

Clayton NP, Jain A, Halasohoris SA, et al. In vitro and in vivo characterization of tebipenem (TBP), an orally active carbapenem, against biothreat pathogens. Antimicrob Agents Chemother. 2021 Feb 16:AAC.02385-20. 

2021
Microbiology
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Zilberberg MD, Nathanson BH, Sulham K, Shorr AF. Multiple antimicrobial resistance and outcomes among hospitalized patients with complicated urinary tract infections in the US, 2013-2018: a retrospective cohort study. BMC Infect Dis. 2021 Feb 8;21(1):159.

2021
HEOR
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

No items found.

Critchley IA, Cotroneo N, Pucci MJ, Jain A, Mendes RE. Resistance among urinary tract pathogens collected in Europe during 2018. J Glob Antimicrob Resist. 2020 Dec;23:439-444.

2020
Microbiology
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Clinical characteristics and demographics of patients with complicated urinary tract infections (cUTI) and antibiotic resistance or treatment failure: a retrospective database analysis

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

SPR720

Microbiology

Evaluating the activity of SPR719 a novel aminobenzimidazole against nontuberculous Mycobacteria

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

PK/PD
Non-Clinical

Characterization of tebipenem pivoxil hydrobromide pharmacokinetics-pharmacodynamics in a neutropenic murine acute pyelonephritis model

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

SPR720

Clinical
PK/PD

Phase 1 first-in-human single-and multiple-ascending dose trial demonstrates pharmacokinetics and tolerability of SPR720, an oral DNA GyrB inhibitor for Mycobacterial infections

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

SPR720

PK/PD
Non-Clinical
Microbiology

Pharmacokinetics/pharmacodynamics of the novel gyrase inhibitor SPR719/SPR720 and clinical dose selection to treat pulmonary Mycobacterium avium complex disease

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

SPR720

Microbiology
Non-Clinical

SPR720, a novel aminobenzimidazole gyrase inhibitor, demonstrates potent efficacy against Mycobacterium avium ATCC 700898 in a chronic C3HeBFeJ mouse infection model

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

SPR206

Microbiology

Activity of SPR206, a polymyxin derivative, compared to colistin alone and in combination against multidrug-resistant Pseudomonas aeruginosa strains

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Hospital admission patterns in adult patients with complicated urinary tract infections: identification of potentially avoidable hospital admissions across US hospitals

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Eligibility and outcomes of conversion to oral (PO) therapy in patients hospitalized with Enterobacteriaceae (ENT) urinary tract infection (UTI) in the United States (US): a multicenter analysis

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Pre and post hospitalization resource utilization and costs associated with urinary tract infection (UTI) in both commercial and Medicare populations

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Tebipenem: An oral carbapenem with activity against multi-drug resistant urinary tract infection isolates of Escherichia coli collected from US medical centers during 2019

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Health resource utilization in patients with complicated urinary tract infections (cUTI) and antibiotic resistance or treatment failure: a retrospective database analysis

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR
Microbiology

Epidemiology of complicated urinary tract infections (cUTIs) presenting in emergency departments across the United States (US)

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Clinical

Oral tebipenem pivoxil hydrobromide is non-inferior to IV ertapenem in complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) – Results from the pivotal ADAPT-PO study.

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

HEOR

Hospital costs and reimbursement in patients with resistant Enterobacteriaceae (ENT) urinary tract infection (UTI) in the United States (US): a multicenter analysis

2020
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Zilberberg MD, Nathanson BH, Sulham K, Shorr AF. Antimicrobial Susceptibility and Cross-Resistance Patterns among Common Complicated Urinary Tract Infections in U.S. Hospitals, 2013 to 2018. Antimicrob Agents Chemother. 2020 Jul 22;64(8):e00346-20. 

2020
HEOR
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Non-Clinical

Cotroneo N, Rubio A, Critchley IA, et al. In vitro and in vivo characterization of tebipenem, an oral carbapenem. Antimicrob Agents Chemother. 2020 Jul 22;64(8):e02240-19.

2020
Microbiology
ARCHIVE
View Full Text Link
Open Resource

SPR720

No items found.

Stokes SS, Vemula R, Pucci MJ. Advancement of GyrB Inhibitors for Treatment of Infections Caused by Mycobacterium tuberculosis and Non-tuberculous Mycobacteria. ACS Infect Dis. 2020 Jun 12;6(6):1323-1331.

2020
Reviews
ARCHIVE
View Full Text Link
Open Resource

SPR206

No items found.

Brown P, Abbott E, Abdulle O, et al. Design of Next Generation Polymyxins with Lower Toxicity: The Discovery of SPR206. ACS Infect Dis. 2019 Oct 11;5(10):1645-1656.

2019
Reviews
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

PK/PD
Non-Clinical

Characterization of tebipenem pharmacokinetics-pharmacodynamics for efficacy against Enterobacteriaceae in a one-compartment in vitro infection model

2019
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Antimicrobial susceptibility patterns of common complicated urinary tract infection pathogens in US Hospitals, 2013-2018

2019
IDWeek
ARCHIVE
View Full Text Link
Open Resource

Tebipenem HBR

Microbiology

Resistance to oral antibiotics among urinary tract infection isolates of Escherichia coli from the United States and Europe in 2017

2019
IDWeek
ARCHIVE
View Full Text Link
Open Resource
No results found.
There are no results with this criteria. Try changing your search.

Unable to find what you were looking for?  

Download a complete bibliography from each of our ongoing investigational programs below.